Featured Press Releases

IKA introduces new accessories for the HABITAT research bioreactor.

IKA introduces new accessories for the HABITAT research bioreactor.

Axion BioSystems extends its agreement with Corning®, granting exclusive rights to distribute its award-winning cell counting device.

Axion BioSystems extends its agreement with Corning®, granting exclusive rights to distribute its award-winning cell counting device.

  • 07 Aug 2024

Axion BioSystems announced an agreement with Corning Incorporated that continues Corning’s...

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

Sapio Sciences Collaborates with the Wellcome Sanger Institute on Transforming Digital Laboratories

Sapio Sciences Collaborates with the Wellcome Sanger Institute on Transforming Digital Laboratories

Approval and Launch of Nintedanib Capsules

Approval and Launch of Nintedanib Capsules

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

Strong Performance Across More Than 200 Customer Audits Highlighted by Piramal Pharma Solutions

  • Piramal Pharma Solutions
  • 22 Jun 2026
Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

Cryo-EM Collaboration Between Gandeeva and Zymeworks Speeds Antibody Drug Discovery

  • Gandeeva Therapeutics Inc.
  • 18 Jun 2026
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

  • Merck & Co., Inc.
  • 18 Jun 2026
Avenacy Announces the U.S. Launch of Bortezomib for Injection

Avenacy Announces the U.S. Launch of Bortezomib for Injection

  • Avenacy
  • 18 Jun 2026
WISE Closes Oversubscribed €30 Million Series D Financing Round with ENEA Tech and Biomedical Joining as Strategic Investor

WISE Closes Oversubscribed €30 Million Series D Financing Round with ENEA Tech and Biomedical Joining as Strategic Investor

  • WISE S.p.A.
  • 17 Jun 2026
Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

  • Rugiet
  • 17 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.